Provided by Tiger Trade Technology Pte. Ltd.

Aurinia Pharmaceuticals

16.05
-0.0600-0.37%
Post-market: 15.96-0.0920-0.57%19:30 EDT
Volume:878.85K
Turnover:14.10M
Market Cap:2.14B
PE:6.97
High:16.26
Open:16.05
Low:15.92
Close:16.11
52wk High:19.25
52wk Low:10.34
Shares:133.05M
Float Shares:129.00M
Volume Ratio:1.16
T/O Rate:0.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.30
EPS(LYR):2.07
ROE:66.12%
ROA:15.49%
PB:3.47
PE(LYR):7.75

Loading ...

Aurinia Pharmaceuticals (AUPH) Is Up 8.4% After Teva Agrees To Delay Generic Voclosporin Launch

Simply Wall St.
·
Aug 26

Aurinia Pharmaceuticals (AUPH) After The Teva Settlement Is The Stock A Bargain

Simply Wall St.
·
Aug 22

Aurinia Shares Gains After Settling Patent Lawsuit with Teva

Dow Jones
·
Aug 20

Aurinia Pharmaceuticals (AUPH) Gets a Buy from TD Cowen

TIPRANKS
·
Aug 20

Aurinia settles patent litigation with Teva

TIPRANKS
·
Aug 20

Aurinia Settles Teva Patent Suit, Bars Generic Voclosporin Launch Until Dec. 7, 2036

Reuters
·
Aug 20

Aurinia Pharmaceuticals - Teva May Launch Generic Voclosporin in U.S. no Earlier than December 7, 2036

THOMSON REUTERS
·
Aug 20

Aurinia Pharmaceuticals - Continues Patent Litigation Against Multiple Generic Companies in New Jersey

THOMSON REUTERS
·
Aug 20

Aurinia Settles Patent Litigation with Teva

THOMSON REUTERS
·
Aug 20

CannaPharmaRx Q2 FY26 Net Loss Widens to USD 1.91 Million; Revenue Rises 19.26% to USD 276,218

Reuters
·
Aug 19

Aurinia Pharmaceuticals is Maintained at Sector Perform by RBC Capital

Dow Jones
·
Aug 08

RBC Adjusts PT on Aurinia Pharmaceuticals to $16 From $15, Keeps Sector Perform Speculative Risk Rating

MT Newswires Live
·
Aug 07

Analysts’ Opinions Are Mixed on These Healthcare Stocks: VistaGen Therapeutics (VTGN), Iovance Biotherapeutics (IOVA) and Aurinia Pharmaceuticals (AUPH)

TIPRANKS
·
Aug 06

Aurinia Pharmaceuticals Q2 EPS $0.28 Beats $0.24 Estimate, Sales $83.220M Beat $79.357M Estimate

Benzinga Earnings
·
Aug 06

Aurinia Publishes Corporate Presentation Outlining Lupkynis Growth Strategy, Aritinercept Development Plans

Reuters
·
Aug 06

Aurinia Pharmaceuticals Q2 Pretax Profit USD 48.786 Million

Reuters
·
Aug 06

Aurinia Pharmaceuticals sees FY26 revenue $315M-$325M, consensus $325.82M

TIPRANKS
·
Aug 06

Aurinia Q2 Net Income Climbs 74% to $37.4 Million; Revenue Rises 19% to $83.2 Million

Reuters
·
Aug 06

Aurinia Pharmaceuticals Q2 Product Revenue USD 79.412 Million

THOMSON REUTERS
·
Aug 06

Press Release: Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress

Dow Jones
·
Aug 06